NetworkNewsBreaks – VIVO Cannabis Inc. (TSX: VIV
Post# of 111
(Total Views: 239)
Posted On: 06/19/2020 3:00:32 PM
NetworkNewsBreaks – VIVO Cannabis Inc. (TSX: VIVO) (OTCQX: VVCIF) Partners with Medipharm Labs to Leverage GMP Production Capabilities, Accelerate Australian Market Presence
VIVO Cannabis (TSX: VIVO) (OTCQX: VVCIF) today announced that its subsidiary, Beacon Medical Australia Pty. Ltd. (“Beacon Medical Australia”), entered into an agreement with MediPharm Labs Australia Pty. Ltd. (“MediPharm Labs Australia”), a subsidiary of MediPharm Labs Corp. (TSX: LABS) (“MediPharm Labs”). Under the agreement, MediPharm Labs Australia will supply pharmaceutical-quality (GMP certified), formulated cannabis oil products to Beacon Medical Australia to sell into the Australian market. “VIVO’s international efforts remain focused on the emerging Australian and German markets and we continue to seek out partnerships with organizations that have proven track records,” Barry Fishman, CEO of VIVO, said in the news release. “For this reason, we are thrilled to be working with MediPharm Labs to leverage their GMP production capabilities to accelerate our Australian market presence. We are confident this will allow us to continue to provide our Australian patients with the medical-grade products they have come to expect from the Beacon Medical(TM) brand.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
VIVO Cannabis (TSX: VIVO) (OTCQX: VVCIF) today announced that its subsidiary, Beacon Medical Australia Pty. Ltd. (“Beacon Medical Australia”), entered into an agreement with MediPharm Labs Australia Pty. Ltd. (“MediPharm Labs Australia”), a subsidiary of MediPharm Labs Corp. (TSX: LABS) (“MediPharm Labs”). Under the agreement, MediPharm Labs Australia will supply pharmaceutical-quality (GMP certified), formulated cannabis oil products to Beacon Medical Australia to sell into the Australian market. “VIVO’s international efforts remain focused on the emerging Australian and German markets and we continue to seek out partnerships with organizations that have proven track records,” Barry Fishman, CEO of VIVO, said in the news release. “For this reason, we are thrilled to be working with MediPharm Labs to leverage their GMP production capabilities to accelerate our Australian market presence. We are confident this will allow us to continue to provide our Australian patients with the medical-grade products they have come to expect from the Beacon Medical(TM) brand.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)VIVO Cannabis Inc. (VVCIF) Stock Research Links
Scroll down for more posts ▼